Rebecca Liang, Ph.D. +852 2123 2656 rebecca.liang@bernsteinsg.com Haopeng Zhou +852 2123 2630 haopeng.zhou@bernsteinsg.com For the exclusive use of JATIN CHAWLA at TVF CAPITAL ADVISORS PTE LTD on 19-Jun-2025 20 June 2025 China Pharma and Biotech China Pharma & Biotech: the out-licensing boom, and can it sustain? Growth in China's license deals to the West was one of our major predictions in the 2025 outlook, but the unprecedented momentum shown by recent mega-deals beats even our expectations. Up till June ...

Group 1 - The period between Memorial Day and Labor Day is identified as the "100 deadliest days of summer," with American teens being 20% more likely to be involved in fatal car collisions during this time [1][2] - Parents play a crucial role in enhancing road safety by engaging in conversations with their teens about the dangers of driving during this period and enforcing strict rules against driving under the influence or distracted driving [3][4] - Mercury Insurance emphasizes the importance of setting a good example for teens, being involved in their driving education, and understanding state driving laws to promote safe driving practices [6][4] Group 2 - Mercury Insurance, headquartered in Los Angeles, offers a range of insurance products including personal auto, homeowners, and renters insurance, and has a strong presence in multiple states [5][6] - The company has been recognized for its competitive rates and excellent customer service, employing over 4,200 staff and working with more than 6,340 independent agents [6][7] - Mercury Insurance has received high ratings from A.M. Best and accolades from Forbes and Insure.com for its auto insurance services [6][7]

Investor Deck I May 2025 1 © 2025 Adeia | All rights reserved. Safe Harbor This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on information available to the Company as of the date hereof, as well as the Company's current expectations, assumptions, estimates and projections that ...

15 June 2025 | 1:53PM HKT Potential opportunities on other technology platforms: Referring to technology platform-based collaborations between China pharma / biotech and MNCs (see summary in Exhibit 1), the upfront payment of US$110mn for the announced AZ/CSPC collaboration is consistent with the historical range of US$10mn to below US$200mn, while the total deal size of US$5.3bn was the highest since 2023. With the current collaboration announced to date, we see growing recognition from MNCs for CSPC's tec ...

Investment Rating - The report maintains a "Buy" rating for several companies in the healthcare sector, including Asymchem, InnoCare, Samsung Biologics, Shandong Weigao Group, United Imaging, and Zai Lab [29][30]. Core Insights - The China biotech sector has seen a significant re-rating, with a year-to-date increase of 72%, driven by a surge in licensing-out deals, particularly in PD-1/VEGF bispecifics, which has validated asset quality and innovation [1][2]. - Investors are optimistic about the sustainability of this momentum, with expectations for more licensing deals to follow, including potential major deals from CSPC and Sino Biopharma [2]. - The CRO/CDMO sector has also benefited from increased licensing activity, with a 25% year-to-date growth, and companies like Tigermed and WuXi AppTec are highlighted for their resilience [8]. - Medtech is showing signs of recovery, with equipment tendering up 91% year-over-year in May, although revenue recognition remains a challenge due to inventory digestion and centralized procurement processes [8][10]. Summary by Sections China Biotech Licensing and Global Pharma Engagement - The rebound in China biotech is largely attributed to licensing deals with global pharma, enhancing confidence in the quality and innovation of Chinese biotech assets [2]. - Notable licensing deals include Akeso to Summit and 3S Bio to Pfizer, which have allowed companies to monetize global market valuations through royalties [2]. CDMO/CRO Implications - The CRO/CDMO sector has seen a 25% increase year-to-date, with Tigermed reporting a 20% year-over-year increase in new orders for Q1 [8]. - WuXi AppTec and Asymchem are expected to deliver resilient earnings due to their focus on late-stage and commercial manufacturing [8]. Medtech Recovery and Tendering Trends - Medtech has faced challenges, with a year-to-date decline of 4%, but there are signs of recovery in equipment tendering, which increased by 91% year-over-year in May [8][10]. - Companies like United Imaging and Mindray are expected to turn positive in their growth trajectories in the coming quarters [8]. Global Pharma Engagement - Global large pharma continues to recognize the importance of China in their business development strategies, particularly in the context of biopharma innovation cycles [10]. - Companies like GE Healthcare and Philips remain cautious about the capital equipment procurement environment in China, despite positive tendering momentum [10].

Summary of Key Points from the Conference Call Industry Overview - The report focuses on the **biopharmaceutical sector in China**, highlighting its resurgence driven by innovation and increased deal activity with multinational corporations (MNCs) [1][2]. Core Insights - **Global Competitiveness**: China's pharma sector is confirmed to be globally competitive, with significant partnerships such as Summit Therapeutics' licensing agreement with Akeso for ivonescimab (up to $5 billion) and Pfizer's deal with 3SBio for SSGJ-707 (up to $6 billion) [2]. - **Investment in Obesity Treatments**: Companies are investing in the obesity treatment space, with notable deals including Merck's $1.9 billion agreement with Hansoh Pharma and Novo's $2 billion deal with United Bio-Technology [2]. - **Long-Term Winners**: AstraZeneca (AZN) and Sanofi (SAN) are identified as long-term winners in the region, with both companies actively investing and expanding their R&D presence in China [7][11]. R&D and Business Development Opportunities - **Rapid R&D Advancement**: China's biopharma industry is shifting from generics to genuine innovation, with improved R&D efficiency and lower costs [8][41]. - **Rich Pipeline of Assets**: MNCs are increasingly seeking business development (BD) deals in China, with a wealth of attractive pipeline assets available for international partnerships [9]. - **Key Asset Types**: Bispecific antibodies, GLP-1 therapies, and antibody-drug conjugates (ADCs) are highlighted as prominent areas for BD opportunities [10][65]. Market Dynamics - **Market Share Growth**: The share of innovative drugs in China's core hospital pharmaceutical market increased from 21% in 2015 to 29% in 2024, with local companies' share rising from 18.7% to 27.8% [24][25]. - **Declining Contribution**: There is a modest decline in China sales as a percentage of global sales among large-cap EU pharma companies, with AstraZeneca's share dropping from 20% in 2020 to an estimated 12% in 2024 [29][31]. Strategic Collaborations - **M&A Activity**: The report notes a boom in M&A activity as companies seek to acquire innovative pipeline assets amid global pricing pressures and patent expirations [40]. - **Emerging Global Innovation Hub**: China is becoming a global hub for innovative drug R&D, with a significant increase in out-licensing deals, reaching a total value of $50.8 billion in 2024 [40][48]. Specific Therapeutic Areas - **Bispecific Antibodies**: The report emphasizes the growing interest in bispecific antibodies, particularly those targeting PD-1/VEGF pathways, with significant licensing deals indicating global confidence in these assets [66][68]. - **GLP-1 Therapies**: The report outlines the evolution of GLP-1 therapies, with a focus on long-acting formulations and oral small molecules, highlighting numerous ongoing clinical trials and licensing deals [70][72]. - **Antibody-Drug Conjugates (ADCs)**: China is emerging as a leader in ADC innovation, with approximately 40% of the global ADC pipeline originating from China and a significant increase in international licensing transactions [77][78]. Conclusion - The biopharmaceutical sector in China is positioned for growth, with strong R&D capabilities, a rich pipeline of innovative assets, and increasing global interest from MNCs. Companies like AstraZeneca and Sanofi are well-positioned to capitalize on these opportunities, while the landscape for innovative therapies continues to evolve rapidly.

Investment Rating - The report maintains a "Buy" rating for Wuxi Apptec, Pharmaron, and Tigermed A/H, while Wuxi Bio and Joinn A/H are rated as "Neutral" [5][107]. Core Insights - The biopharma industry in China is expected to see a mild increase in R&D activities and outsourcing over the next 12 months, with an average R&D budget increase of 10.8% YoY and an outsourcing rate rising from 46.7% to 48.3% [2][14]. - Biopharma managers are increasingly considering out-licensing as a primary financing option, rising from 58% in 2024 to 75% in 2025, which is anticipated to benefit CROs/CDMOs [3][16]. - The demand for R&D speed and capacity is growing, with biopharma companies prioritizing on-time delivery and quality when selecting CROs [3][50]. Summary by Sections R&D Budget and Outsourcing - Biopharma managers expect their R&D budgets to increase by an average of 10.8% YoY, with a higher willingness to allocate more funds to outsourcing [23][34]. - The overall outsourcing ratio is projected to increase from 46.7% to 48.3% in the next 12 months, with late-stage trials expected to recover more than early-stage trials [34][50]. Business Development (BD) Activities - 75% of surveyed biopharma managers view BD as the primary financing option, reflecting a significant increase in BD activities [3][16]. - The report indicates that the reinvestment of BD income may lead to more CRO orders, enhancing growth opportunities for CROs/CDMOs [16][50]. Pricing Trends - Biopharma managers anticipate smaller price cuts in the next 12 months compared to the previous year, indicating an improving demand/supply situation [4][56]. - The report highlights that no price cuts are expected for manufacturing in the upcoming year, which is a positive sign for the industry [4][56]. Vendor Selection - Wuxi Apptec remains the top choice for preclinical lab-testing, while Tigermed is the preferred vendor for clinical testing and trials [5][74]. - The criteria for selecting CROs emphasize quality, on-time delivery, and reputation, with a growing importance placed on delivery speed [65][92]. Market Outlook - The survey results suggest an overall positive outlook for the CRO/CDMO sector in China, with expectations of improved R&D activity and outsourcing compared to 2024 [5][50]. - The geopolitical uncertainties are expected to have limited impact on the operations of China CROs, with less than 10% of Wuxi Apptec's goods subject to US tariffs [5][107].

Asia Pacific Equity Research 12 June 2025 (852) 2800 8195 denise.yan@jpmorgan.com J.P. Morgan Securities (Asia Pacific) Limited/ J.P. Morgan Broking (Hong Kong) Limited J P M O R G A N Correction (first published 11 June 2025) (See disclosures for details) China Biotech Thoughts on the road ahead for Innovent, Akeso and Kelun-Biotech As we continue to receive questions on Innovent, Akeso and Kelun-Biotech during our marketing tour and in light of recent news flow on these three names, we offer some of our q ...

Core Insights - Energy Transfer LP (ET) has significant exposure to the Chinese ethane market through its Orbit joint venture with Satellite Petrochemical, making China a crucial destination for ET's ethane exports [1][9] - New licensing requirements from the U.S. Commerce Department, effective May 2025, introduce uncertainty regarding existing agreements and future shipment volumes to China [2][9] - The licensing rule could delay or block ethane shipments, posing risks to ET's operations and revenues, especially at its Mont Belvieu and Nederland export terminals [2][9] Licensing Impact - Energy Transfer is preparing to apply for the necessary export licenses and is assessing the potential impact of denied or delayed authorizations on export volumes and revenue streams related to China [3] - Other ethane exporters, such as Enterprise Products Partners (EPD) and Phillips 66 (PSX), may also face challenges due to the new licensing requirements, with EPD already experiencing a notice of intent to refuse export licenses for shipments to China [5][6] Financial Performance - ET's stock has increased by 3.2% over the past three months, contrasting with a 4.3% decline in the Zacks Oil and Gas - Production Pipeline - MLB industry [7] - The Zacks Consensus Estimate indicates year-over-year earnings growth for ET of 12.5% in 2025 and 1.88% in 2026, with current estimates for earnings per unit at $1.44 for 2025 and $1.47 for 2026 [12][13] Valuation Metrics - ET's current trailing 12-month EV/EBITDA ratio is 10.18X, which is lower than the industry average of 11.08X, suggesting that the company is undervalued compared to its peers [14][16] - Enterprise Products Partners is also trading at a discount with an EV/EBITDA of 10.07X [16] Zacks Rank - Energy Transfer holds a Zacks Rank of 2 (Buy), indicating a favorable outlook compared to other stocks in the market [17]

InterDigital (IDCC) FY Conference Summary Company Overview - InterDigital is a technology company founded in 1972, specializing in foundational research in wireless, video, and artificial intelligence [6][7] - The company has built a large and evergreen patent portfolio, licensing it to major vendors in the industry [7][8] - InterDigital employs around 500 people across 14 sites in 7 countries, focusing on hiring top talent from leading universities [11][12] Business Model and Strategy - The business model is centered on foundational technology, investing in research to stay ahead of the curve by 5 to 10 years [10][11] - The company participates in standard development, which drives value creation and technology dissemination [14][21] - InterDigital has a high concentration of inventors, with over 90% of employees being scientists and engineers [13] Financial Performance - The company has signed over 40 agreements with an economic value exceeding $3.7 billion in the last four years [33] - Revenue growth has been approximately 20-25% CAGR over the past four years, with adjusted EBITDA margins increasing [35][36] - The company has increased its dividend by 50% in the last twelve months and reduced share outstanding by 45% since 2011 [36] Market Opportunities - The mobile ecosystem has an economic impact of approximately $5.7 trillion, making it the third-largest GDP if considered a separate country [38] - InterDigital's core markets include smartphones, consumer electronics, and IoT, with a significant opportunity identified in cloud-based streaming video [39][40] - The smartphone market is expected to grow from over $400 million to $500 million in recurring revenue [42] Patent Portfolio - The patent portfolio has nearly doubled from 2017 to 2025, with a focus on wireless communication technology [29] - InterDigital's patent quality is ranked number one in 5G, top five in video, and top ten in WiFi [31] Capital Allocation - The company maintains a strong balance sheet and invests 50% of recurring revenue back into R&D [54] - InterDigital is optimistic about future M&A opportunities, having previously acquired Technicolor's patent assets [55] Licensing Agreements - 94% of revenue in 2024 is expected to come from fixed fee agreements, minimizing exposure to volume fluctuations [64] - The largest contract with Apple is a seven-year deal signed in 2022, providing stable revenue [66] Litigation and Customer Relations - InterDigital rarely resorts to litigation, focusing on bilateral negotiations for licensing agreements [71][73] - The company emphasizes fairness in licensing, ensuring that all competitors pay their fair share for using its technology [72][74] Long-Term Growth Strategy - The company aims to grow recurring revenue at 14% year-over-year, targeting over $600 million in adjusted EBITDA by 2030 [57] - Investments will continue in next-generation technologies, including 6G and advanced AI [57] Conclusion - InterDigital is positioned for significant growth with a strong patent portfolio, innovative technology, and a clear strategy for expanding into new markets [58]